Department of Obstetrics and Gynecology, University Hospital of Schleswig-Holstein, Campus Luebeck, Germany.
Institute of Social Medicine and Epidemiology, University of Luebeck, Germany.
Breast Care (Basel). 2014 Oct;9(5):349-54. doi: 10.1159/000366435.
The purpose of the study was to characterize the treatment of young mothers with breast cancer in Germany and to investigate whether it followed applicable guidelines.
Retrospective data obtained between 2002 and 2011 for 1,053 mothers with children of < 12 years of age with adjuvantly treated loco-regional primary breast cancer were analyzed. Collected data included sociodemographic data, TNM stage, biology of tumor and therapies. Actually received therapies were compared to those suggested in guideline treatment plans.
The mean age of the patients was 39 years. 97% of the women with node positivity received an axillary dissection. Overall, 90% of the patients received chemotherapy with a guideline adherence range of 87-99% depending on clinical parameters. For radiation therapy, guideline adherence was high (range 82-100%). 95% of the patients with a hormone receptor-positive tumor received endocrine therapy; in 94%, tamoxifen therapy was performed in compliance with guidelines, whereas gonadotropin-releasing hormone (GnRH) agonist therapy complied with the guidelines in 52% of the cases.
Guideline adherence in young mothers with breast cancer in Germany was high (with the exception of GnRH therapy), as comorbidity or the ambiguity of the therapeutic success does not need to be considered as much in this young, otherwise usually healthy, cohort compared to an age-heterogeneous group.
本研究旨在描述德国年轻乳腺癌患者的治疗特征，并探讨其是否符合适用的指南。
回顾性分析了 2002 年至 2011 年间 1053 例年龄<12 岁的接受辅助局部区域原发性乳腺癌治疗的年轻母亲患者的数据。收集的数据包括社会人口统计学数据、TNM 分期、肿瘤生物学和治疗方法。实际接受的治疗方法与指南治疗方案中的建议进行了比较。
患者的平均年龄为 39 岁。97%的淋巴结阳性患者接受了腋窝清扫术。总体而言，90%的患者接受了化疗，根据临床参数，指南的遵循率为 87%-99%。对于放射治疗，指南的遵循率较高（范围为 82%-100%）。95%的激素受体阳性肿瘤患者接受了内分泌治疗；在 94%的患者中，他莫昔芬治疗符合指南，而促性腺激素释放激素（GnRH）激动剂治疗在 52%的患者中符合指南。
德国年轻乳腺癌患者的指南遵循率较高（除 GnRH 治疗外），因为与年龄不同的患者相比，年轻、通常健康的这一患者群体无需考虑过多的合并症或治疗效果的不确定性。
